Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry

Autor: Lacramioara Perju-Dumbrava, Lars Bergmann, Anjum Misbahuddin, Francesc Valldeoriola, Stephen Wørlich Pedersen, Chris van der Linden, Stephan Bohlhalter, Erik H. Danielsen, David, Maurizio Zibetti, Björn Hauptmann, Oriol De Fabregues, Ashley Yegin, Martin Nevrly, K. Ray Chaudhuri, Jeff Blackie, M.M. Ponsen, Christoph Redecker, Anne Jeanjean, Kenn Freddy Pedersen, Jan Kassubek, Mihaela Simu, Philippe Busson, Barbara A. Pickut, Pierre R. Burkhard, József Attila Szász, Per Odin, Bogdan Ovidiu Popescu, Ene Amalia, Angelo Antonini, Robert Jech, Thomas E. Kimber, Matthias Bode, Kari Anne Bjørnarå, Ivan Milanov, Bruno Bergmans, Espen Dietrichs, Luc Defebvre, Christofer Lundqvist, Jesper Clausen, Michaela Kaiserová, Valérie Delvaux, Werner Poewe, Martin Wolz, Sophie Dethy, Jaime Kulisevsky, Cleanthe Spanaki, Anette Storstein, Michel Rijntjes, F. Ory Magne, Pietro Marano, T. van Laar, Tove Henriksen, Christian Winkler, Ovidiu Bajenaru, Spyridon Konitsiotis, Michel Van Zandijcke, Ransmayr Gerhard, F. Viallet, Koray Onuk, Guy Arnold, Kirsten Hahn, Jo Leenders, Mariachiara Sensi, Jorge Hernández-Vara, Zikos Panayiotis, Nicola Modugno, Volker Tomantschger, Matilde Calopa, Zvezdan Pirtošek, Paul Bourgeois, Graziano Gusmaroli, Christoph Schrader, Ioan Buraga, Víctor Puente, Rejko Krüger, Alexander Storch, Tatiana Witjas
Přispěvatelé: UCL - SSS/IONS/NEUR - Clinical Neuroscience, UCL - (SLuc) Service de neurologie, GLORIA study co-investigators, Movement Disorder (MD)
Jazyk: angličtina
Rok vydání: 2017
Předmět:
0301 basic medicine
Male
Parkinson's disease
Neurology
Routine patient care
Levodopa-carbidopa intestinal gel
Motor symptoms
Non-motor symptoms
Antiparkinson Agents
Levodopa
0302 clinical medicine
Quality of life
Gériatrie - gérontologie
Medicine
Registries
Parkinson Disease/drug therapy
Intubation
Gastrointestinal
Carbidopa/administration & dosage
Carbidopa
Parkinson Disease
Middle Aged
Safety profile
Drug Combinations
Female
medicine.symptom
Gastrointestinal
medicine.medical_specialty
Levodopa/administration & dosage
03 medical and health sciences
Rating scale
Internal medicine
Neurologie
Antiparkinson Agents/administration & dosage
Humans
Aged
business.industry
medicine.disease
nervous system diseases
ddc:616.8
030104 developmental biology
Mood
Dyskinesia
Levodopa carbidopa
Physical therapy
Geriatrics and Gerontology
Neurology (clinical)
Human medicine
Intubation
business
Gels
030217 neurology & neurosurgery
Zdroj: Parkinsonism & related disorders, Vol. 45, p. 13-20 (2017)
Parkinsonism & related disorders, 45
Antonini, A, Poewe, W, Chaudhuri, K R, Jech, R, Pickut, B, Pirtošek, Z, Szasz, J, Valldeoriola, F, Winkler, C, Bergmann, L, Yegin, A, Onuk, K, Barch, D, Odin, P, Amalia, E, Arnold, G, Bajenaru, O, Bergmans, B, Bjornara, K A, Blackie, J, Bode, M, Bourgeois, P, Bohlhalter, S, Buraga, I, Burkhard, P R, Busson, P, Calopa, M, Clausen, J, Danielsen, E H, Defebvre, L, Delvaux, V, Dethy, S, Dietrichs, E, De Fabregues, O, Gerhard, R, Gusmaroli, G, Hahn, K, Hauptmann, B, Henriksen, T, Hernandez-Vara, J, Jeanjean, A, Kaiserova, M, Kassubek, J, Kimber, T, Konitsiotis, S, Krüger, R, Kulisevsky, J, Leenders, J, Lundqvist, C, Ory Magne, F & GLORIA study co-investigators 2017, ' Levodopa-carbidopa intestinal gel in advanced Parkinson's : Final results of the GLORIA registry ', Parkinsonism and Related Disorders, vol. 45, pp. 13-20 . https://doi.org/10.1016/j.parkreldis.2017.09.018
PARKINSONISM & RELATED DISORDERS
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Parkinsonism and related disorders
Parkinsonism & Related Disorders, Vol. 45 (2017) pp. 13-20
Parkinsonism & Related Disorders, 45, 13-20. Elsevier
Antonini, A, Poewe, W, Chaudhuri, K R, Jech, R, Pickut, B, Pirtošek, Z, Szasz, J, Valldeoriola, F, Winkler, C, Bergmann, L, Yegin, A, Onuk, K, Barch, D, Odin, P, Amalia, E, Arnold, G, Bajenaru, O, Bergmans, B, Bjornara, K A, Blackie, J, Bode, M, Bourgeois, P, Bohlhalter, S, Buraga, I, Burkhard, P R, Busson, P, Calopa, M, Clausen, J, Danielsen, E H, Defebvre, L, Delvaux, V, Dethy, S, Dietrichs, E, De Fabregues, O, Gerhard, R, Gusmaroli, G, Hahn, K, Hauptmann, B, Henriksen, T, Hernandez-Vara, J, Jeanjean, A, Kaiserova, M, Kassubek, J, Kimber, T, Konitsiotis, S, Krüger, R, Kulisevsky, J, Leenders, J, Lundqvist, C, Ory Magne, F, Marano, P, Milanov, I, Modugno, N, Misbahuddin, A, Nevrly, M, Panayiotis, Z, Pedersen, K F, Pedersen, S W, Perju-Dumbrava, L, Ponsen, M M, Popescu, B O, Rijntjes, M, Puente, V, Redecker, C, Schrader, C, Sensi, M, Simu, M, Spanaki, C, Storch, A, Storstein, A, Tomantschger, V, van der Linden, C, van Laar, T, Viallet, F, Witjas, T, Wolz, M, Zibetti, M & Van Zandijcke, M 2017, ' Levodopa-carbidopa intestinal gel in advanced Parkinson's : Final results of the GLORIA registry ', Parkinsonism & Related Disorders . https://doi.org/10.1016/j.parkreldis.2017.09.018
ISSN: 1353-8020
DOI: 10.1016/j.parkreldis.2017.09.018
Popis: Introduction This registry evaluated the 24-month safety and efficacy of levodopa-carbidopa intestinal gel (LCIG) treatment in advanced Parkinson's disease (PD) patients under routine clinical care. Methods Motor fluctuations, dyskinesia, non-motor symptoms, quality of life, and safety were evaluated. Observations were fully prospective for treatment-naïve patients (60% of patients) and partially retrospective for patients with ≤12 months of pre-treatment with LCIG (40% of patients). Hours of “On” and “Off” time were assessed with a modified version of the Unified Parkinson's Disease Rating Scale part IV items 32 and 39. Results Overall, 375 patients were enrolled by 75 movement disorder centers in 18 countries and 258 patients completed the registry. At 24 months LCIG treatment led to significant reductions from baseline in “Off” time (hours/day) (mean ± SD = −4.1 ± 3.5, P < 0.001), “On” time with dyskinesia (hours/day) (−1.1 ± 4.8, P = 0.006), Non-Motor Symptom Scale total (−16.7 ± 43.2, P < 0.001) and individual domains scores, and Parkinson's Disease Questionnaire-8 item total score (−7.1 ± 21.0, P < 0.001). Adverse events deemed to have a possible/probable causal relationship to treatment drug/device were reported in 194 (54%) patients; the most frequently reported were decreased weight (6.7%), device related infections (5.9%), device dislocations (4.8%), device issues (4.8%), and polyneuropathy (4.5%). Conclusions LCIG treatment led to sustained improvements in motor fluctuations, non-motor symptoms particularly sleep/fatigue, mood/cognition and gastrointestinal domains, as well as quality of life in advanced PD patients over 24 months. Safety events were consistent with the established safety profile of LCIG.
0
SCOPUS: ar.j
info:eu-repo/semantics/published
Databáze: OpenAIRE
Externí odkaz: